SecBot SecBot
Biotech Drug Report Generated Aug 1, 2026

GIVLAARI

ALNY·ALNYLAM PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (FDA approval 2019-11-20)
Time to market
Already approved and on the market, FDA approval recorded 2019-11-20; no new regulatory decision pending.
Why 3/10
GIVLAARI was FDA-approved on 2019-11-20 and has no PDUFA, pivotal readout or other hard dated regulatory binary scheduled in the next ~12 months, it is an approved, commercialized product and only one of several marketed drugs at Alnylam, so it scores 3 per the approved-drug-no-binary rule.
Actionable Insight NEUTRAL

Watch Alnylam's quarterly earnings for the TTR-franchise trajectory and total product revenue, since GIVLAARI's own newsflow is minimal now that it is approved, do not expect a Givlaari-specific binary in the next 12 months. For a trade on ALNY itself, the near-term drivers are the ATTR-CM (vutrisiran/patisiran) commercial ramp and the Regeneron cemdisiran NDA (filed 2026-04-30), not this drug. Re-verify the drug's label/mechanism and any competitive or pricing news with live web sources, since DuckDuckGo was unavailable during this session.

Price Chart

Loading chart...

Executive Summary

GIVLAARI (givosiran) is Alnylam's RNAi therapy for acute hepatic porphyria, approved by the FDA on 2019-11-20 per SecBot's catalyst/outcome records (the stock moved +13.55% the day of and +14.8% over five days around that approval). It is an established commercial product in an ultra-rare disease, so it is a steady but small contributor to Alnylam (ALNY, Nasdaq, confirmed via SEC-derived index), whose value now rests mainly on the larger TTR-amyloidosis franchise.

How It Works

GIVLAARI is a small interfering RNA (RNAi) medicine, a short piece of synthetic genetic material injected under the skin once a month that travels to liver cells and "silences" a specific gene (ALAS1). That gene makes an enzyme that drives the buildup of toxic heme-building chemicals; in people with acute hepatic porphyria those chemicals trigger severe, sometimes dangerous abdominal/neurological attacks. By turning down ALAS1, GIVLAARI reduces attack-driving toxins at their source.

Trial Status

Approved and commercialized for acute hepatic porphyria (AHP); no givosiran Phase 2/3 trial records appear in SecBot's local ClinicalTrials.gov ingestion window, and no upcoming regulatory catalyst for this drug is on record, the only ALNY FDA catalyst in the past year is Regeneron's cemdisiran NDA (2026-04-30), a different molecule.

The Two-Sided Case

▲ Bull Case5
Regulatory binary is behind it: GIVLAARI already won FDA approval with a +13.55% 1-day / +14.8% 5-day stock reaction, no approval risk remains for this drug.
It addresses a genuine unmet need as a first-in-class RNAi treatment for acute hepatic porphyria attacks, giving it a defensible niche in an ultra-rare indication.
Parent company sentiment is broadly constructive: analyst consensus shows 21 Buy + 8 Strong Buy vs 9 Hold and 0 Sell, with a mean price target of $427.61 vs a ~$205.52 quote (implied upside ~106.8%), and Q2 2026 revenue grew ~74% YoY per the local 8-K earnings analysis.
Short interest is not extreme: 5,773,373 shares short at the 2026-07-15 settlement = ~4.32% of estimated shares outstanding, ~3.24 days to cover.
Small planned insider sales (10b5-1) and some institutional adds (e.g., Robeco +48.7%, per the local 13F change report) do not indicate distress specific to this product.
▼ Bear Case4
AHP is ultra-rare, so GIVLAARI's commercial ceiling is small, it is a minor product within a company whose stock is primarily driven by the TTR franchise (vutrisiran/patisiran), meaning Givlaari-specific news rarely moves ALNY.
ALNY shares have been hammered: -39.5% over 12 months, -40.7% over 6 months, RSI ~23.5, and a -59 composite quant score as of 2026-07-31, the dominant narrative is the TTR launch slowdown, not this drug.
Q2 2026 results missed: non-GAAP EPS $1.84 vs $2.15 consensus and revenue $1.291B vs $1.32B, with FY2026 TTR net product revenue guidance cut from $4.4-4.7B to $4.2-4.5B, the local earnings analysis rated the release bearish (impact 7).
Mixed institutional flow: several funds exited/trimmed ALNY in 2026-Q1/Q2 (e.g., Jane Street near-exit -98.1%, Parnassus exit -100%), and daily FINRA short-volume ratios in July 2026 ran ~55-69% of off-exchange volume (flow, not outstanding short interest).

Upcoming Catalysts

  • No hard dated catalyst for GIVLAARI itself (approved, no pending PDUFA/readout).
  • Alnylam quarterly earnings (next after the 2026-07-30 Q2 release), total product revenue and TTR guidance updates.
  • Regeneron/Alnylam cemdisiran NDA (gMG) review milestones, a different molecule but an ALNY-relevant regulatory event.
  • Continued commercial ramp and any payer/formulary developments for the approved portfolio.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ALNYLAM PHARMACEUTICALS, INC. 8-K ALNY ·Originating report

Sources · 3

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov